Q1 Earnings Estimate for PHIO Issued By HC Wainwright

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Phio Pharmaceuticals in a research report issued on Friday, March 6th. HC Wainwright analyst M. Keller expects that the company will earn ($0.24) per share for the quarter. HC Wainwright has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.00.

Phio Pharmaceuticals Stock Down 0.9%

Shares of PHIO stock opened at $1.16 on Monday. The firm has a market cap of $13.48 million, a price-to-earnings ratio of -0.80 and a beta of 0.90. Phio Pharmaceuticals has a 52-week low of $0.81 and a 52-week high of $4.19. The company’s 50 day moving average is $1.11 and its 200 day moving average is $1.55.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.19.

Institutional Trading of Phio Pharmaceuticals

A hedge fund recently raised its stake in Phio Pharmaceuticals stock. Cetera Investment Advisers increased its holdings in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 26.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,500 shares of the company’s stock after buying an additional 9,000 shares during the quarter. Cetera Investment Advisers owned 0.39% of Phio Pharmaceuticals worth $45,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 57.31% of the stock is currently owned by institutional investors and hedge funds.

About Phio Pharmaceuticals

Phio Pharmaceuticals, Inc (NASDAQ: PHIO) is a clinical‐stage biotechnology company focused on the discovery and development of dual RNA interference (RNAi) therapeutics. Utilizing its proprietary Transitional RNAi (TRiMTM) platform, Phio aims to simultaneously silence multiple gene targets to achieve enhanced therapeutic activity. The company’s core mission is to advance next‐generation RNAi compounds with potential applications in oncology and immuno‐oncology.

Phio’s TRiMTM platform is designed around the delivery of synthetic, double‐stranded RNA duplexes that can be engineered to target specific combinations of genes implicated in tumor growth and immune evasion.